A Phase 1, Open-label, Single-center, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Octreotide Acetate Injection (Sandostatin(R)) on the Pharmacokinetics of Single-dose Telotristat Etiprate in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2016
Price : $35 *
At a glance
- Drugs Telotristat etiprate (Primary) ; Octreotide
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Lexicon Pharmaceuticals
- 06 Sep 2016 Status changed from active, no longer recruiting to completed.
- 05 Sep 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 05 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.